What is BridgeBio Pharma's operating income?

BridgeBio Pharma's total operating income in 2025 was -$523.41 million, based on the following breakdown: Total Gross Profit: $481.11 million Total Operating Expenses: $1.00 billion

BridgeBio Pharma (BBIO) Financials

$81.21 -2.63 (-3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$80.12 -1.09 (-1.34%)

As of 05:53 PM Eastern

Compare

Annual Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-31	-131	-261	-449	-563	-481	-643	-536	-725
Consolidated Net Income / (Loss)	-44	-169	-289	-505	-586	-485	-653	-543	-733
Net Income / (Loss) Continuing Operations	-44	-169	-289	-505	-586	-485	-653	-543	-733
Total Pre-Tax Income	-44	-169	-289	-505	-586	-485	-653	-542	-733
Total Operating Income	-44	-184	-266	-474	-577	-512	-607	-593	-523
Total Gross Profit	0.00	0.00	41	8.25	67	74	6.86	218	481
Total Revenue	0.00	0.00	41	8.25	70	78	9.30	222	502
Operating Revenue	0.00	0.00	41	8.25	70	78	9.30	222	502
Total Cost of Revenue	0.00	0.00	0.00	0.00	3.11	3.43	2.45	3.88	21
Operating Cost of Revenue	-	-	0.00	-	3.11	3.43	2.45	3.88	21
Total Operating Expenses	44	184	307	483	643	586	614	811	1,005
Selling, General & Admin Expense	13	44	94	146	192	143	151	289	531
Research & Development Expense	31	140	210	337	451	399	456	506	452
Restructuring Charge	-	-	-	0.00	0.00	44	7.93	16	21
Total Other Income / (Expense), net	0.03	14	-22	-31	-9.82	28	-46	51	-209
Interest Expense	0.01	2.55	8.77	37	47	80	81	126	199
Interest & Investment Income	0.04	21	-12	4.02	1.13	7.54	18	164	-53
Other Income / (Expense), net	0.00	-4.30	-1.63	1.63	36	100	17	12	43
Income Tax Expense	-	-	-	-	-	0.00	0.00	1.15	0.44
Net Income / (Loss) Attributable to Noncontrolling Interest	-13	-39	-28	-57	-24	-3.47	-10	-7.59	-8.01
Basic Earnings per Share	($1.00)	($2.12)	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)	($3.78)
Weighted Average Basic Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	147.47M	162.79M	186.08M	191.53M
Diluted Earnings per Share	($1.00)	($2.12)	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)	($3.78)
Weighted Average Diluted Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	147.47M	162.79M	186.08M	191.53M
Weighted Average Basic & Diluted Shares Outstanding	30.60M	61.77M	105.10M	118.00M	144.36M	151.37M	175.83M	190.19M	193.86M

This table shows BridgeBio Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-168	-35	-73	-162	-265	-167	-182	-183	-193	-164	-152
Consolidated Net Income / (Loss)	-170	-36	-76	-164	-267	-170	-184	-185	-195	-167	-156
Net Income / (Loss) Continuing Operations	-170	-36	-76	-164	-267	-170	-184	-185	-195	-167	-156
Total Pre-Tax Income	-170	-36	-76	-164	-266	-170	-182	-186	-195	-167	-156
Total Operating Income	-177	0.34	-176	-192	-226	-104	-134	-145	-140	-106	-107
Total Gross Profit	1.15	211	3.14	2.13	3.80	114	107	114	146	185	229
Total Revenue	1.75	211	4.34	2.73	5.88	117	111	121	154	195	244
Operating Revenue	1.75	211	4.34	2.73	5.88	117	111	121	154	195	244
Total Cost of Revenue	0.60	0.60	1.20	0.60	2.08	2.64	3.65	6.56	8.11	9.94	15
Operating Cost of Revenue	0.60	0.60	1.20	0.60	2.08	2.64	3.65	6.56	8.11	9.94	15
Total Operating Expenses	179	210	177	194	230	218	241	259	286	291	336
Selling, General & Admin Expense	48	66	60	69	95	106	129	138	158	164	186
Research & Development Expense	130	141	115	120	130	111	111	113	116	127	149
Restructuring Charge	0.75	3.40	2.89	4.62	4.69	0.57	0.81	8.84	11	0.00	0.00
Total Other Income / (Expense), net	7.09	-37	100	27	-40	-65	-47	-41	-55	-61	-49
Interest Expense	20	50	23	23	30	63	38	48	50	53	55
Interest & Investment Income	5.58	4.08	124	49	-12	-10	-16	-9.60	-17	-12	0.22
Other Income / (Expense), net	22	9.48	-0.63	1.80	1.62	8.23	6.55	16	12	4.25	5.59
Income Tax Expense	-	-	0.00	0.00	-	-	2.10	-1.55	-	-	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.18	-0.94	-2.09	-2.21	-2.34	-2.19	-1.86	-2.19	-1.77	-2.51	-3.68
Basic Earnings per Share	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)	($0.88)	($0.95)	($0.95)	($1.00)	($0.84)	($0.78)
Weighted Average Basic Shares Outstanding	162.79M	178.71M	187.59M	188.51M	186.08M	190.15M	190.52M	191.85M	191.53M	194.79M	195.79M
Diluted Earnings per Share	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)	($0.88)	($0.95)	($0.95)	($1.00)	($0.84)	($0.78)
Weighted Average Diluted Shares Outstanding	162.79M	178.71M	187.59M	188.51M	186.08M	190.15M	190.52M	191.85M	191.53M	194.79M	195.79M
Weighted Average Basic & Diluted Shares Outstanding	175.83M	187.13M	188.03M	188.99M	190.19M	189.88M	191.17M	192.71M	193.86M	195.86M	195.49M

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	72	344	-72	-5.52	38	21	-22	289	-111
Net Cash From Operating Activities	-40	-137	-254	-400	-498	-419	-528	-521	-446
Net Cash From Continuing Operating Activities	-40	-137	-254	-400	-498	-419	-529	-521	-446
Net Income / (Loss) Continuing Operations	-44	-169	-289	-505	-586	-485	-653	-543	-733
Consolidated Net Income / (Loss)	-44	-169	-289	-505	-586	-485	-653	-543	-733
Depreciation Expense	-	-	0.86	1.46	5.84	6.77	6.49	6.08	5.43
Amortization Expense	-	0.00	-	-	-	-	13	7.46	5.97
Non-Cash Adjustments To Reconcile Net Income	2.10	10	45	86	61	30	100	-23	320
Changes in Operating Assets and Liabilities, net	1.24	22	-11	18	21	28	5.06	32	-45
Net Cash From Investing Activities	-0.46	-21	-217	-53	-201	453	54	61	-24
Net Cash From Continuing Investing Activities	-0.46	-21	-217	-53	-201	453	54	61	-24
Purchase of Property, Plant & Equipment	-0.46	-2.18	-2.64	-7.52	-13	-4.82	-1.31	-0.93	-1.10
Acquisitions	0.00	-16	0.00	0.00	-35	-1.50	0.00	-8.12	-8.50
Purchase of Investments	0.00	0.00	-213	-288	-643	-193	-137	-114	-28
Sale and/or Maturity of Investments	-	0.00	0.00	249	477	533	193	184	13
Net Cash From Financing Activities	113	502	399	447	736	-13	452	748	359
Net Cash From Continuing Financing Activities	113	502	397	447	733	-13	452	748	359
Repayment of Debt	0.13	55	-0.82	-13	-140	-20	0.00	-489	-471
Repurchase of Common Equity	0.00	0.00	0.00	-75	-200	-	0.00	0.00	-48
Payment of Dividends	-1.15	-44	-55	-5.00	-	-	-0.80	0.00	2.15
Issuance of Debt	4.00	1.00	37	550	1,204	0.00	0.00	450	575
Issuance of Common Equity	0.00	96	391	25	3.82	7.41	453	319	6.41
Other Financing Activities, net	2.98	59	25	-35	-49	-0.90	-0.87	469	295
Cash Interest Paid	0.00	1.57	6.09	15	30	54	61	91	44
Cash Income Taxes Paid	-	-	-	-	-	-	0.00	0.00	1.20

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-129	83	72	-142	275	-141	208	-106	-73	310	-202
Net Cash From Operating Activities	-125	-220	75	-181	-195	-199	-81	-110	-56	-197	-71
Net Cash From Continuing Operating Activities	-125	-220	75	-181	-195	-199	-81	-110	-56	-197	-71
Net Income / (Loss) Continuing Operations	-170	-36	-76	-164	-267	-170	-184	-185	-195	-167	-156
Consolidated Net Income / (Loss)	-170	-36	-76	-164	-267	-170	-184	-185	-195	-167	-156
Depreciation Expense	1.59	1.60	1.57	1.54	1.37	1.28	1.32	1.40	1.44	1.19	1.05
Amortization Expense	-	-	-	-	-	1.62	-	-	1.45	1.82	1.93
Non-Cash Adjustments To Reconcile Net Income	10	40	137	-16	56	84	82	73	79	91	87
Changes in Operating Assets and Liabilities, net	34	-225	12	-2.32	14	-116	19	-3.93	56	-125	-5.62
Net Cash From Investing Activities	-0.07	23	3.04	38	-3.24	-1.60	-13	4.46	-14	-43	18
Net Cash From Continuing Investing Activities	-0.07	23	3.04	38	-3.24	-1.60	-13	4.46	-14	-43	18
Purchase of Property, Plant & Equipment	-0.44	-0.70	-0.05	-0.14	-0.05	0.00	-0.59	-0.47	-0.03	-0.07	-0.44
Purchase of Investments	-29	-65	-49	-	-	0.00	-7.91	-2.97	-17	-53	-11
Sale and/or Maturity of Investments	30	89	55	40	-	0.00	-	10	3.00	10	30
Net Cash From Financing Activities	-4.52	280	-5.73	0.71	474	60	302	-0.89	-2.18	550	-149
Net Cash From Continuing Financing Activities	-4.52	280	-5.73	0.71	474	60	302	-0.89	-2.18	550	-149
Repayment of Debt	-	-486	-3.73	-	-	-471	-	-6.90	6.90	-24	11
Repurchase of Common Equity	-	0.00	-	-	-	-48	-	-	-	-83	-128
Other Financing Activities, net	-4.07	-2.40	-1.50	-1.41	474	0.75	302	1.28	-9.68	19	-32

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	465	632	704	1,013	623	546	919	936
Total Current Assets	445	569	643	889	549	478	721	798
Cash & Equivalents	436	364	356	394	377	376	681	570
Short-Term Investments	0.00	182	251	443	95	59	0.00	17
Accounts Receivable	-	2.85	-	-	-	1.75	4.72	139
Inventories, net	-	-	-	-	-	-	0.00	27
Prepaid Expenses	9.14	20	36	32	22	24	35	44
Plant, Property, & Equipment, net	1.58	5.63	20	30	15	12	7.01	5.37
Total Noncurrent Assets	18	57	40	94	60	57	192	133
Long-Term Investments	17	31	-	-	-	0.00	144	80
Intangible Assets	-	-	0.00	45	29	26	24	28
Other Noncurrent Operating Assets	1.09	26	40	49	31	31	24	25
Total Liabilities & Shareholders' Equity	465	632	704	1,013	623	546	919	936
Total Liabilities	88	156	596	1,878	1,868	1,889	2,377	3,013
Total Current Liabilities	33	60	96	135	121	144	154	288
Short-Term Debt	-	0.00	1.46	-	-	-	-	0.00
Accounts Payable	14	8.85	8.95	12	12	11	9.62	36
Accrued Expenses	12	26	46	81	67	66	34	41
Current Deferred Revenue	-	-	-	0.00	8.16	6.10	15	7.19
Current Employee Benefit Liabilities	4.05	13	30	37	31	57	58	77
Other Current Liabilities	3.01	12	9.35	4.94	3.68	4.13	38	126
Total Noncurrent Liabilities	55	95	500	1,743	1,747	1,745	2,223	2,725
Long-Term Debt	55	92	92	431	431	446	1,721	1,852
Noncurrent Deferred Revenue	-	-	-	-	-	3.73	17	13
Other Noncurrent Operating Liabilities	0.50	3.53	408	1,313	1,316	1,295	484	859
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.12	2.24	1.63	1.42	-1.59	0.48	0.14	-0.57
Total Equity & Noncontrolling Interests	377	474	106	-867	-1,243	-1,343	-1,458	-2,076
Total Preferred & Common Equity	315	408	58	-870	-1,255	-1,354	-1,468	-2,087
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	315	408	58	-870	-1,255	-1,354	-1,468	-2,087
Common Stock	494	848	1,021	842	939	1,481	1,903	2,058
Retained Earnings	-179	-440	-889	-1,437	-1,918	-2,561	-3,096	-3,821
Treasury Stock	-	0.00	-75	-275	-275	-275	-275	-323
Accumulated Other Comprehensive Income / (Loss)	0.00	0.25	0.19	-0.13	-0.33	0.03	0.01	0.01
Noncontrolling Interest	62	65	48	3.41	11	11	10	11

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	626	504	655	849	794	665	882	1,080	998	1,371	1,217
Total Current Assets	553	433	588	783	616	445	695	912	839	1,241	1,093
Cash & Equivalents	407	302	505	475	408	266	541	749	643	880	678
Short-Term Investments	84	81	38	44	40	0.00	-	7.94	2.99	60	42
Accounts Receivable	-	-	-	-	-	-	115	77	117	205	254
Inventories, net	-	-	-	-	-	-	3.95	18	25	33	53
Prepaid Expenses	25	21	23	28	28	38	35	60	52	63	66
Plant, Property, & Equipment, net	14	13	12	11	9.84	8.70	6.70	6.11	5.83	4.94	5.23
Total Noncurrent Assets	59	58	55	54	168	212	180	162	153	125	119
Long-Term Investments	-	-	-	-	117	160	128	108	92	62	55
Intangible Assets	28	28	27	26	25	25	28	30	29	27	27
Other Noncurrent Operating Assets	31	30	28	29	26	27	24	24	32	36	37
Total Liabilities & Shareholders' Equity	626	504	655	849	794	665	882	1,080	998	1,371	1,217
Total Liabilities	1,839	1,853	1,849	1,886	1,876	1,883	2,520	2,859	2,921	3,640	3,723
Total Current Liabilities	97	110	106	141	134	139	152	176	217	816	891
Short-Term Debt	-	-	-	-	-	-	-	-	-	547	548
Accounts Payable	4.08	3.87	4.47	4.73	18	13	28	26	19	29	27
Accrued Expenses	63	68	57	86	67	66	34	31	35	54	64
Current Deferred Revenue	6.68	6.21	6.59	14	15	12	12	11	9.09	6.12	5.55
Current Employee Benefit Liabilities	19	29	34	32	29	44	33	37	56	39	50
Other Current Liabilities	3.67	3.78	4.14	4.54	4.62	4.60	46	71	98	140	196
Total Noncurrent Liabilities	1,743	1,743	1,743	1,745	1,742	1,744	2,368	2,683	2,704	2,823	2,833
Long-Term Debt	436	440	442	435	435	436	0.00	0.00	1,851	1,926	1,928
Noncurrent Deferred Revenue	-	-	-	20	17	19	18	15	13	12	10
Other Noncurrent Operating Liabilities	1,307	1,303	1,301	1,290	1,290	1,289	2,351	2,668	840	886	895
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-0.20	0.33	1.40	0.53	-0.22	0.65	-0.23	-0.45	0.02	-0.95	-1.02
Total Equity & Noncontrolling Interests	-1,213	-1,350	-1,195	-1,037	-1,082	-1,219	-1,638	-1,778	-1,923	-2,268	-2,505
Total Preferred & Common Equity	-1,226	-1,362	-1,208	-1,050	-1,093	-1,230	-1,648	-1,788	-1,933	-2,278	-2,515
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,226	-1,362	-1,208	-1,050	-1,093	-1,230	-1,648	-1,788	-1,933	-2,278	-2,515
Common Stock	1,107	1,128	1,460	1,821	1,851	1,876	1,939	1,981	2,019	2,113	2,156
Retained Earnings	-2,057	-2,215	-2,392	-2,596	-2,669	-2,831	-3,264	-3,446	-3,628	-3,985	-4,137
Treasury Stock	-275	-275	-275	-275	-275	-275	-323	-323	-323	-406	-533
Accumulated Other Comprehensive Income / (Loss)	-0.01	0.06	0.03	0.00	-0.00	0.01	0.00	0.00	0.00	-0.01	-0.01
Noncontrolling Interest	12	12	12	12	11	11	9.96	9.89	10	10	10

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	-79.66%	745.14%	11.38%	-88.02%	2,285.27%	126.26%
EBITDA Growth	0.00%	-328.56%	-42.06%	-76.55%	-13.49%	24.30%	-44.08%	1.52%	17.32%
EBIT Growth	0.00%	-328.56%	-42.51%	-76.52%	-14.37%	23.86%	-43.29%	1.58%	17.28%
NOPAT Growth	0.00%	-318.76%	-44.96%	-78.22%	-21.53%	11.17%	-18.58%	2.37%	11.73%
Net Income Growth	0.00%	-286.59%	-70.31%	-75.16%	-16.02%	17.36%	-34.79%	16.82%	-34.89%
EPS Growth	0.00%	-112.00%	-16.98%	-53.23%	-2.63%	16.41%	-21.17%	27.09%	-31.25%
Operating Cash Flow Growth	0.00%	-237.49%	-85.58%	-57.62%	-24.57%	15.75%	-25.80%	1.33%	14.37%
Free Cash Flow Firm Growth	0.00%	0.00%	-84.78%	132.19%	625.00%	-166.23%	-30.97%	120.57%	97.01%
Invested Capital Growth	0.00%	0.00%	55.94%	-4,225.81%	-213.74%	-4.10%	-1.80%	-36.93%	-58.90%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-62.41%	22.41%	-12.42%	-1.33%	1.90%	42.79%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-10.36%	-2.24%	3.06%	-5.62%	-13.64%	17.96%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-10.70%	-2.43%	2.98%	-5.54%	-13.43%	16.75%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-11.48%	-7.08%	6.63%	-8.62%	-8.93%	14.18%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-11.19%	-3.03%	2.36%	-4.77%	-21.75%	9.03%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-12.09%	0.26%	2.69%	-1.54%	-19.01%	10.21%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-13.31%	-5.28%	-8.18%	8.83%	-6.36%	-15.66%	23.75%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-2.43%	80.97%	-144.75%	123.95%	96.28%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-1.61%	-1.73%	-5,495.73%	-2.72%	-36.85%	-10.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	95.53%	95.58%	73.71%	98.25%	95.82%
EBITDA Margin	0.00%	0.00%	-658.30%	-5,714.54%	-767.35%	-521.57%	-6,272.23%	-258.95%	-93.40%
Operating Margin	0.00%	0.00%	-656.41%	-5,751.99%	-827.12%	-659.65%	-6,528.75%	-267.22%	-104.25%
EBIT Margin	0.00%	0.00%	-660.42%	-5,732.19%	-775.73%	-530.29%	-6,342.04%	-261.69%	-95.67%
Profit (Net Income) Margin	0.00%	0.00%	-711.50%	-6,127.87%	-841.20%	-624.17%	-7,021.94%	-244.86%	-145.98%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.21%	100.06%
Interest Burden Percent	99.94%	90.15%	107.73%	106.90%	108.44%	117.70%	110.72%	93.37%	152.49%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-44.90%	-67.64%	-173.15%	154.80%	45.93%	50.49%	38.81%	41.48%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-48.85%	-70.82%	-63.02%	-50.34%	-100.91%	-79.24%	-51.78%
Return on Assets (ROA)	0.00%	0.00%	-52.63%	-75.71%	-68.34%	-59.25%	-111.72%	-74.14%	-79.01%
Return on Common Equity (ROCE)	0.00%	-37.47%	-57.33%	-138.31%	166.00%	46.24%	50.91%	39.11%	41.72%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-53.81%	-70.65%	-872.95%	67.38%	38.63%	48.24%	37.02%	0.00%
Net Operating Profit after Tax (NOPAT)	-31	-129	-186	-332	-404	-359	-425	-415	-366
NOPAT Margin	0.00%	0.00%	-459.49%	-4,026.40%	-578.98%	-461.75%	-4,570.13%	-187.06%	-72.97%
Net Nonoperating Expense Percent (NNEP)	0.00%	-20.51%	-23.13%	-34.72%	-39.77%	-52.01%	-543.39%	-65.32%	35.22%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	44.14%	47.42%	40.68%	163.90%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	4.47%	4.42%	26.29%	1.75%	4.18%
SG&A Expenses to Revenue	0.00%	0.00%	232.63%	1,766.08%	275.70%	184.41%	1,618.73%	130.21%	105.81%
R&D to Revenue	0.00%	0.00%	517.62%	4,085.91%	646.94%	514.45%	4,898.54%	228.24%	90.02%
Operating Expenses to Revenue	0.00%	0.00%	756.41%	5,851.99%	922.65%	755.22%	6,602.46%	365.48%	200.07%
Earnings before Interest and Taxes (EBIT)	-44	-188	-268	-473	-541	-412	-590	-581	-480
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-44	-188	-267	-471	-535	-405	-584	-575	-469
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.11	10.60	150.52	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	1.11	10.60	150.52	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	106.79	1,056.59	35.21	14.67	754.92	23.37	29.36
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	96.49	1,000.44	29.46	13.78	755.64	21.67	31.74
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	129.31	4.44	0.00	0.00	58.26	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.14	0.19	0.87	-0.50	-0.35	-0.33	-0.30	-0.89
Long-Term Debt to Equity	0.00	0.14	0.19	0.86	-0.50	-0.35	-0.33	-0.30	-0.89
Financial Leverage	0.00	-1.06	-1.04	-1.71	1.21	0.23	0.03	0.14	-0.59
Leverage Ratio	0.00	1.23	1.29	2.29	-2.27	-0.78	-0.45	-0.52	-0.53
Compound Leverage Factor	0.00	1.11	1.38	2.44	-2.46	-0.91	-0.50	-0.49	-0.80
Debt to Total Capital	0.00%	12.62%	16.17%	46.53%	-99.06%	-52.95%	-49.82%	-42.86%	-826.59%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.72%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	12.62%	16.17%	45.81%	-99.06%	-52.95%	-49.82%	-42.86%	-826.59%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	14.47%	11.89%	24.77%	-1.11%	-1.19%	-1.31%	-1.01%	-4.48%
Common Equity to Total Capital	0.00%	72.91%	71.94%	28.70%	200.17%	154.14%	151.13%	143.87%	931.06%
Debt to EBITDA	0.00	-0.29	-0.34	-0.20	-0.81	-1.06	-0.77	-0.76	-3.95
Net Debt to EBITDA	0.00	2.12	1.82	1.09	0.76	0.19	0.01	0.67	-2.53
Long-Term Debt to EBITDA	0.00	-0.29	-0.34	-0.20	-0.81	-1.06	-0.77	-0.76	-3.95
Debt to NOPAT	0.00	-0.42	-0.49	-0.28	-1.07	-1.20	-1.05	-1.05	-5.06
Net Debt to NOPAT	0.00	3.10	2.60	1.55	1.01	0.22	0.01	0.93	-3.23
Long-Term Debt to NOPAT	0.00	-0.42	-0.49	-0.28	-1.07	-1.20	-1.05	-1.05	-5.06
Altman Z-Score	0.00	1.58	15.35	5.74	-2.00	-5.18	-7.14	-4.51	-3.28
Noncontrolling Interest Sharing Ratio	0.00%	16.56%	15.23%	20.13%	-7.23%	-0.69%	-0.83%	-0.79%	-0.58%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	13.67	9.42	6.72	6.58	4.52	3.32	4.67	2.77
Quick Ratio	0.00	13.39	9.09	6.35	6.34	4.03	3.04	4.44	2.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-107	-198	64	463	-306	-401	83	-36
Operating Cash Flow to CapEx	-8,725.86%	-6,273.78%	-9,612.85%	-5,316.76%	-3,759.13%	0.00%	-40,407.35%	-55,812.00%	-40,648.13%
Free Cash Flow to Firm to Interest Expense	0.00	-42.13	-22.62	1.74	9.89	-3.81	-4.94	0.66	-0.18
Operating Cash Flow to Interest Expense	-3,114.46	-53.65	-28.93	-10.90	-10.64	-5.22	-6.49	-4.14	-2.24
Operating Cash Flow Less CapEx to Interest Expense	-3,150.15	-54.50	-29.23	-11.11	-10.93	-5.15	-6.51	-4.14	-2.24
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.07	0.01	0.08	0.09	0.02	0.30	0.54
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	68.56	6.97
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	11.27	0.64	2.77	3.48	0.71	23.57	81.13
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.30	0.29	0.22	0.38	0.91
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.32	52.40
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	1,220.71	1,245.83	1,657.35	954.05	399.15
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	-1,220.71	-1,245.83	-1,657.35	-948.73	-346.74
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-21	-9.37	-405	-1,272	-1,324	-1,348	-1,845	-892
Invested Capital Turnover	0.00	0.00	-2.65	-0.04	-0.08	-0.06	-0.01	-0.14	-0.69
Increase / (Decrease) in Invested Capital	0.00	-21	12	-396	-866	-52	-24	-498	-330
Enterprise Value (EV)	0.00	12	3,913	8,253	2,053	1,070	7,030	4,809	15,935
Market Capitalization	349	349	4,331	8,716	2,455	1,139	7,023	5,186	14,740
Book Value per Share	$0.00	$5.10	$3.31	$0.47	($5.91)	($8.39)	($7.78)	($7.77)	($10.83)
Tangible Book Value per Share	$0.00	$5.10	$3.31	$0.47	($6.22)	($8.59)	($7.94)	($7.89)	($10.97)
Total Capital	0.00	432	568	202	-435	-814	-896	-1,020	-224
Total Debt	0.00	55	92	94	431	431	446	437	1,852
Total Long-Term Debt	0.00	55	92	92	431	431	446	437	1,852
Net Debt	0.00	-399	-485	-513	-406	-79	-5.09	-388	1,185
Capital Expenditures (CapEx)	0.46	2.18	2.64	7.52	13	-5.18	1.31	0.93	1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-23	-38	-58	-83	-82	-118	-115	-78
Debt-free Net Working Capital (DFNWC)	0.00	413	508	549	754	427	334	566	510
Net Working Capital (NWC)	0.00	413	508	547	754	427	334	566	510
Net Nonoperating Expense (NNE)	13	41	102	173	183	126	228	128	367
Net Nonoperating Obligations (NNO)	0.00	-399	-485	-513	-406	-79	-5.09	-388	1,185
Total Depreciation and Amortization (D&A)	0.00	0.00	0.86	1.46	5.84	6.77	6.49	6.08	11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-93.09%	-708.68%	-119.13%	-106.15%	-1,266.13%	-51.80%	-15.48%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	1,253.05%	6,650.92%	1,081.23%	550.46%	3,587.54%	255.20%	101.53%
Net Working Capital to Revenue	0.00%	0.00%	1,253.05%	6,633.24%	1,081.23%	550.46%	3,587.54%	255.20%	101.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)	($3.78)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	123.77M	148.96M	147.61M	147.47M	162.79M	186.08M	191.53M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	($3.26)	($3.95)	($2.88)	($3.78)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	123.77M	148.96M	147.61M	147.47M	162.79M	186.08M	191.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($2.48)	($3.80)	($3.90)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	105.10M	118.00M	144.36M	151.37M	175.83M	190.19M	193.86M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-129	-186	-332	-404	-328	-420	-404	-351
Normalized NOPAT Margin	0.00%	0.00%	-459.49%	-4,026.40%	-578.98%	-422.30%	-4,510.49%	-182.13%	-70.00%
Pre Tax Income Margin	0.00%	0.00%	-711.50%	-6,127.87%	-841.20%	-624.17%	-7,021.94%	-244.34%	-145.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3,373.69	-73.80	-30.56	-12.90	-11.56	-5.12	-7.26	-4.61	-2.41
NOPAT to Interest Expense	-2,361.58	-50.48	-21.26	-9.06	-8.63	-4.46	-5.23	-3.30	-1.84
EBIT Less CapEx to Interest Expense	-3,409.38	-74.65	-30.86	-13.11	-11.84	-5.05	-7.27	-4.62	-2.41
NOPAT Less CapEx to Interest Expense	-2,397.28	-51.33	-21.56	-9.27	-8.91	-4.39	-5.25	-3.30	-1.84
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-2.63%	-26.10%	-19.06%	-0.99%	0.00%	0.00%	0.00%	0.00%	0.29%
Augmented Payout Ratio	-2.63%	-26.10%	-19.06%	-15.83%	-34.10%	0.00%	0.00%	0.00%	-6.29%

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	193,862,871.00	195,861,242.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	193,862,871.00	195,861,242.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.85	-0.78
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.68%	11,461.88%	32.11%	-33.22%	237.08%	-44.76%	2,449.93%	4,318.01%	4,051.27%	66.78%	120.39%
EBITDA Growth	-25.23%	109.13%	-22.11%	-16.78%	-44.78%	-930.48%	27.60%	32.42%	44.82%	-5.86%	21.18%
EBIT Growth	-24.84%	107.75%	-21.81%	-16.55%	-44.18%	-1,078.43%	27.50%	32.23%	43.07%	-5.79%	20.54%
NOPAT Growth	-37.28%	100.27%	-20.15%	-21.60%	-27.40%	-30,529.15%	23.51%	24.28%	38.25%	-1.52%	20.26%
Net Income Growth	-21.17%	74.67%	52.99%	8.49%	-56.98%	-369.05%	-143.25%	-12.59%	27.21%	1.80%	15.17%
EPS Growth	-6.59%	78.26%	60.20%	20.37%	-47.42%	-340.00%	-143.59%	-10.47%	30.07%	4.55%	17.89%
Operating Cash Flow Growth	-33.86%	-52.12%	165.90%	-24.33%	-56.49%	9.25%	-208.00%	39.32%	71.12%	0.98%	11.87%
Free Cash Flow Firm Growth	-161.69%	-141.29%	-107.24%	-108.30%	438.23%	745.11%	1,511.46%	-554.50%	124.64%	-242.44%	-259.59%
Invested Capital Growth	-1.80%	13.34%	-2.89%	-2.78%	-36.93%	-105.66%	-95.68%	39.94%	-58.90%	65.46%	69.52%
Revenue Q/Q Growth	-57.35%	11,998.57%	-98.97%	26.01%	115.30%	1,882.88%	-5.20%	9.17%	27.74%	26.16%	25.27%
EBITDA Q/Q Growth	4.51%	107.41%	-1,628.60%	-7.91%	-18.37%	57.47%	-33.27%	-0.73%	1.95%	20.95%	0.19%
EBIT Q/Q Growth	4.50%	106.31%	-1,892.91%	-7.82%	-18.14%	57.16%	-32.86%	-0.79%	0.77%	20.39%	0.21%
NOPAT Q/Q Growth	-12.51%	100.19%	-51,277.55%	-9.24%	-17.88%	53.82%	-28.65%	-8.13%	3.88%	24.08%	-1.06%
Net Income Q/Q Growth	5.10%	78.77%	-108.92%	-117.43%	-62.79%	36.57%	-8.34%	-0.64%	-5.24%	14.43%	6.40%
EPS Q/Q Growth	10.19%	79.38%	-95.00%	-120.51%	-66.28%	38.46%	-7.95%	0.00%	-5.26%	16.00%	7.14%
Operating Cash Flow Q/Q Growth	14.05%	-75.88%	134.03%	-341.71%	-8.17%	-2.00%	59.50%	-35.81%	48.51%	-249.66%	63.96%
Free Cash Flow Firm Q/Q Growth	-108.52%	-71.85%	50.76%	-15.19%	447.01%	227.76%	7.74%	-153.41%	136.36%	-780.69%	-20.70%
Invested Capital Q/Q Growth	-2.72%	16.75%	-20.40%	0.18%	-36.85%	-25.05%	-14.56%	69.36%	-10.09%	10.60%	-1.08%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.73%	99.72%	72.42%	78.11%	64.57%	97.74%	96.70%	94.56%	94.74%	94.89%	93.83%
EBITDA Margin	-8,828.25%	5.41%	-8,053.37%	-6,896.60%	-3,791.84%	-81.33%	-114.33%	-105.50%	-80.98%	-50.74%	-40.43%
Operating Margin	-10,167.11%	0.16%	-8,096.82%	-7,018.67%	-3,842.69%	-89.49%	-121.45%	-120.30%	-90.52%	-54.47%	-43.94%
EBIT Margin	-8,919.08%	4.65%	-8,125.97%	-6,952.89%	-3,815.08%	-82.43%	-115.52%	-106.66%	-82.85%	-52.29%	-41.65%
Profit (Net Income) Margin	-9,760.92%	-17.13%	-3,484.50%	-6,012.23%	-4,545.89%	-145.42%	-166.20%	-153.22%	-126.24%	-85.63%	-63.97%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.43%	100.00%	101.16%	99.17%	99.94%	100.00%	100.00%
Interest Burden Percent	109.44%	-368.00%	42.88%	86.47%	118.64%	176.42%	142.22%	144.85%	152.46%	163.77%	153.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	50.49%	48.58%	37.96%	37.00%	38.81%	50.59%	54.89%	51.30%	41.48%	37.36%	32.77%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-141.91%	1.38%	-2,743.52%	-2,294.11%	-1,155.17%	-12.14%	-28.80%	-45.10%	-44.84%	-26.92%	-25.85%
Return on Assets (ROA)	-155.30%	-5.08%	-1,176.45%	-1,983.74%	-1,376.45%	-21.41%	-41.43%	-64.78%	-68.32%	-44.09%	-39.71%
Return on Common Equity (ROCE)	50.91%	49.12%	38.32%	37.39%	39.11%	51.02%	55.27%	51.66%	41.72%	37.54%	32.92%
Return on Equity Simple (ROE_SIMPLE)	0.00%	52.09%	42.23%	36.29%	0.00%	41.06%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-124	0.24	-123	-134	-158	-73	-94	-102	-98	-74	-75
NOPAT Margin	-7,116.97%	0.11%	-5,667.77%	-4,913.07%	-2,689.88%	-62.64%	-85.01%	-84.21%	-63.36%	-38.13%	-30.76%
Net Nonoperating Expense Percent (NNEP)	-109.91%	-43.82%	40.81%	-24.20%	-55.60%	-25.61%	-15.84%	16.95%	9.31%	23.01%	19.38%
Return On Investment Capital (ROIC_SIMPLE)	13.85%	-	-	-	15.51%	4.46%	5.29%	141.69%	43.70%	-36.07%	255.06%
Cost of Revenue to Revenue	34.27%	0.28%	27.58%	21.89%	35.43%	2.26%	3.30%	5.44%	5.26%	5.11%	6.17%
SG&A Expenses to Revenue	2,726.82%	31.17%	2,745.53%	2,519.00%	1,611.39%	91.20%	116.81%	114.02%	102.53%	84.26%	76.44%
R&D to Revenue	7,462.81%	66.77%	5,290.36%	4,408.64%	2,216.08%	95.54%	100.60%	93.52%	75.51%	65.10%	61.33%
Operating Expenses to Revenue	10,232.84%	99.55%	8,169.23%	7,096.78%	3,907.26%	187.22%	218.14%	214.86%	185.26%	149.36%	137.77%
Earnings before Interest and Taxes (EBIT)	-156	9.83	-176	-190	-224	-96	-128	-129	-128	-102	-101
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-154	11	-175	-188	-223	-95	-126	-127	-125	-99	-99
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	754.92	24.61	21.63	21.98	23.37	51.60	35.09	28.24	29.36	24.82	20.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	755.64	24.28	20.45	21.44	21.67	46.43	31.43	31.43	31.74	27.38	22.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	58.26	8.49	8.82	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.33	-0.42	-0.40	-0.36	-0.30	0.00	0.00	-0.96	-0.89	-1.09	-0.99
Long-Term Debt to Equity	-0.33	-0.42	-0.40	-0.36	-0.30	0.00	0.00	-0.96	-0.89	-0.85	-0.77
Financial Leverage	0.03	0.07	0.10	0.10	0.14	0.28	0.40	-0.31	-0.59	-0.21	-0.20
Leverage Ratio	-0.45	-0.66	-0.53	-0.55	-0.52	-0.65	-0.66	-0.53	-0.53	-0.58	-0.54
Compound Leverage Factor	-0.49	2.41	-0.23	-0.47	-0.62	-1.14	-0.93	-0.77	-0.80	-0.94	-0.82
Debt to Total Capital	-49.82%	-72.20%	-67.34%	-55.77%	-42.86%	0.00%	0.00%	-2,581.14%	-826.59%	1,208.47%	-8,141.71%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	267.47%	-1,802.19%
Long-Term Debt to Total Capital	-49.82%	-72.20%	-67.34%	-55.77%	-42.86%	0.00%	0.00%	-2,581.14%	-826.59%	940.99%	-6,339.53%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-1.31%	-2.10%	-1.68%	-1.47%	-1.01%	-0.59%	-0.53%	-14.42%	-4.48%	4.64%	-30.66%
Common Equity to Total Capital	151.13%	174.30%	169.01%	157.24%	143.87%	100.59%	100.53%	2,695.56%	931.06%	-1,113.10%	8,272.37%
Debt to EBITDA	-0.77	-0.97	-0.91	-0.86	-0.76	0.00	0.00	-3.24	-3.95	-5.21	-5.53
Net Debt to EBITDA	0.01	0.19	0.56	0.26	0.67	0.00	0.00	-1.95	-2.53	-3.10	-3.80
Long-Term Debt to EBITDA	-0.77	-0.97	-0.91	-0.86	-0.76	0.00	0.00	-3.24	-3.95	-4.06	-4.30
Debt to NOPAT	-1.05	-1.29	-1.22	-1.14	-1.05	0.00	0.00	-4.34	-5.06	-6.73	-7.10
Net Debt to NOPAT	0.01	0.25	0.75	0.34	0.93	0.00	0.00	-2.61	-3.23	-4.01	-4.88
Long-Term Debt to NOPAT	-1.05	-1.29	-1.22	-1.14	-1.05	0.00	0.00	-4.34	-5.06	-5.24	-5.53
Altman Z-Score	-4.52	-1.37	-2.92	-4.50	-3.23	-3.09	-2.10	-2.37	-2.04	-1.15	-1.90
Noncontrolling Interest Sharing Ratio	-0.83%	-1.10%	-0.95%	-1.05%	-0.79%	-0.84%	-0.71%	-0.70%	-0.58%	-0.49%	-0.44%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.32	5.54	4.59	3.19	4.67	4.57	5.19	3.88	2.77	1.52	1.23
Quick Ratio	3.04	5.34	3.34	1.92	4.44	4.31	4.74	3.52	2.52	1.40	1.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-100	-172	-85	-98	339	1,112	1,198	-640	233	-1,585	-1,913
Operating Cash Flow to CapEx	-28,694.02%	-31,588.06%	138,338.89%	-131,800.00%	-415,587.23%	0.00%	-13,582.66%	-23,313.62%	-170,969.70%	-285,911.59%	-16,049.89%
Free Cash Flow to Firm to Interest Expense	-4.95	-3.44	-3.70	-4.24	11.38	17.58	31.84	-13.30	4.63	-30.00	-35.01
Operating Cash Flow to Interest Expense	-6.16	-4.39	3.26	-7.83	-6.55	-3.15	-2.14	-2.28	-1.12	-3.74	-1.30
Operating Cash Flow Less CapEx to Interest Expense	-6.18	-4.40	3.25	-7.84	-6.55	-3.15	-2.16	-2.29	-1.12	-3.74	-1.31
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.30	0.34	0.33	0.30	0.15	0.25	0.42	0.54	0.51	0.62
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	68.56	0.00	0.00	0.00	6.97	3.62	4.30
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.53	1.12
Fixed Asset Turnover	0.71	17.50	19.15	20.63	23.57	14.07	29.30	48.39	81.13	99.66	125.84
Accounts Payable Turnover	0.22	0.54	0.22	0.27	0.38	0.37	0.38	0.89	0.91	1.00	1.49
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	5.32	0.00	0.00	0.00	52.40	100.85	84.80
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	238.50	327.30
Days Payable Outstanding (DPO)	1,657.35	671.43	1,678.51	1,360.74	954.05	994.45	964.36	408.05	399.15	365.38	245.46
Cash Conversion Cycle (CCC)	-1,657.35	-671.43	-1,678.51	-1,360.74	-948.73	-994.45	-964.36	-408.05	-346.74	-26.03	166.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,348	-1,122	-1,351	-1,348	-1,845	-2,307	-2,643	-810	-892	-797	-806
Invested Capital Turnover	-0.01	-0.18	-0.16	-0.16	-0.14	-0.07	-0.12	-0.33	-0.69	-0.37	-0.41
Increase / (Decrease) in Invested Capital	-24	173	-38	-36	-498	-1,185	-1,292	539	-330	1,510	1,838
Enterprise Value (EV)	7,030	5,307	4,482	4,669	4,809	5,916	7,344	11,053	15,935	15,878	16,297
Market Capitalization	7,023	5,379	4,740	4,787	5,186	6,575	8,199	9,929	14,740	14,396	14,588
Book Value per Share	($7.78)	($5.87)	($5.84)	($6.54)	($7.77)	($8.67)	($9.42)	($10.11)	($10.83)	($11.75)	($12.84)
Tangible Book Value per Share	($7.94)	($6.02)	($5.97)	($6.67)	($7.89)	($8.81)	($9.57)	($10.26)	($10.97)	($11.89)	($12.98)
Total Capital	-896	-602	-647	-782	-1,020	-1,639	-1,778	-72	-224	205	-30
Total Debt	446	435	435	436	437	0.00	0.00	1,851	1,852	2,474	2,475
Total Long-Term Debt	446	435	435	436	437	0.00	0.00	1,851	1,852	1,926	1,928
Net Debt	-5.09	-85	-269	-130	-388	-669	-865	1,113	1,185	1,472	1,700
Capital Expenditures (CapEx)	0.44	0.70	0.05	0.14	0.05	0.00	0.59	0.47	0.03	0.07	0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-118	122	-105	-100	-115	2.47	-20	-23	-78	32	30
Debt-free Net Working Capital (DFNWC)	334	642	482	305	566	543	736	623	510	972	750
Net Working Capital (NWC)	334	642	482	305	566	543	736	623	510	425	202
Net Nonoperating Expense (NNE)	46	36	-47	30	109	97	90	83	97	92	81
Net Nonoperating Obligations (NNO)	-5.09	-85	-269	-130	-388	-669	-865	1,113	1,185	1,472	1,700
Total Depreciation and Amortization (D&A)	1.59	1.60	1.57	1.54	1.37	1.28	1.32	1.40	2.89	3.01	2.98
Debt-free, Cash-free Net Working Capital to Revenue	-1,266.13%	55.87%	-48.06%	-46.09%	-51.80%	1.94%	-8.76%	-6.59%	-15.48%	5.56%	4.25%
Debt-free Net Working Capital to Revenue	3,587.54%	293.67%	219.91%	140.23%	255.20%	426.22%	315.19%	177.12%	101.53%	167.67%	105.24%
Net Working Capital to Revenue	3,587.54%	293.67%	219.91%	140.23%	255.20%	426.22%	315.19%	177.12%	101.53%	73.27%	28.40%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)	($0.88)	($0.95)	($0.95)	($1.00)	($0.84)	($0.78)
Adjusted Weighted Average Basic Shares Outstanding	162.79M	178.71M	187.59M	188.51M	186.08M	190.15M	190.52M	191.85M	191.53M	194.79M	195.79M
Adjusted Diluted Earnings per Share	($0.97)	($0.20)	($0.39)	($0.86)	($1.43)	($0.88)	($0.95)	($0.95)	($1.00)	($0.84)	($0.78)
Adjusted Weighted Average Diluted Shares Outstanding	162.79M	178.71M	187.59M	188.51M	186.08M	190.15M	190.52M	191.85M	191.53M	194.79M	195.79M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	175.83M	187.13M	188.03M	188.99M	190.19M	189.88M	191.17M	192.71M	193.86M	195.86M	195.49M
Normalized Net Operating Profit after Tax (NOPAT)	-124	2.62	-121	-131	-155	-73	-93	-95	-90	-74	-75
Normalized NOPAT Margin	-7,086.73%	1.24%	-5,574.43%	-4,794.67%	-2,634.03%	-62.30%	-84.50%	-79.08%	-58.31%	-38.13%	-30.76%
Pre Tax Income Margin	-9,760.92%	-17.13%	-3,484.50%	-6,012.23%	-4,526.28%	-145.42%	-164.30%	-154.50%	-126.32%	-85.63%	-63.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.68	0.20	-7.68	-8.24	-7.53	-1.52	-3.39	-2.67	-2.54	-1.93	-1.86
NOPAT to Interest Expense	-6.13	0.00	-5.36	-5.82	-5.31	-1.15	-2.50	-2.11	-1.94	-1.40	-1.37
EBIT Less CapEx to Interest Expense	-7.70	0.18	-7.68	-8.24	-7.53	-1.52	-3.41	-2.68	-2.54	-1.93	-1.87
NOPAT Less CapEx to Interest Expense	-6.15	-0.01	-5.36	-5.83	-5.31	-1.15	-2.51	-2.12	-1.94	-1.41	-1.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.29%	0.19%	0.09%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.29%	-11.12%	-29.83%

Financials Breakdown Chart

Key Financial Trends

BridgeBio Pharma (NASDAQ: BBIO) showed meaningful top-line growth in Q1 2026, but the company remains deeply unprofitable and carries a heavy debt load. The latest quarter suggests improving commercial momentum and a stronger cash position, but investors should also note persistent operating losses, negative equity, and reliance on financing to support the business.

Revenue accelerated year over year. Q1 2026 revenue rose to $194.5 million from $116.6 million in Q1 2025, a strong increase that points to improving commercial traction.
Gross profit remains solid. Gross profit reached $184.6 million in Q1 2026, showing the company can generate strong margin dollars before operating costs.
Cash and investments improved materially. BridgeBio ended Q1 2026 with $879.9 million in cash and equivalents and $60.3 million in short-term investments, giving it a sizable liquidity cushion.
Balance-sheet cash increased sharply. Cash and equivalents jumped from $642.9 million at Q3 2025 to $879.9 million at Q1 2026, helped by financing activity.
Revenue growth has been consistent over the past year. Quarterly revenue has generally trended higher, from $116.6 million in Q1 2025 to $154.2 million in Q4 2025 and $194.5 million in Q1 2026.
Operating expenses remain very high. SG&A and R&D totaled $290.5 million in Q1 2026, which still overwhelmed gross profit and produced an operating loss.
Shares outstanding are creeping higher. Basic weighted average shares rose to 194.8 million in Q1 2026 from 190.1 million in Q1 2025, indicating continued dilution pressure.
The company generated negative operating cash flow. Despite strong revenue, operating activities used $197.3 million in cash during Q1 2026.
BridgeBio remains unprofitable. Q1 2026 net loss was $166.6 million, or $(0.84) per share, showing the business is still far from break-even.
Debt is substantial. Long-term debt stood at $1.93 billion in Q1 2026, up from $1.85 billion in Q3 2025, leaving the company with significant financial leverage.

Bottom line: BridgeBio is showing real revenue momentum and has ample cash today, but the company is still burning cash and carrying significant debt. For retail investors, the story is a tradeoff between promising growth and a still-high-risk balance sheet.

08/13/26 10:36 PM ETAI Generated. May Contain Errors.

BridgeBio Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BridgeBio Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BridgeBio Pharma's net income appears to be on an upward trend, with a most recent value of -$732.94 million in 2025, rising from -$43.83 million in 2017. The previous period was -$543.35 million in 2024. Find out what analysts predict for BridgeBio Pharma in the coming months.

BridgeBio Pharma's total operating income in 2025 was -$523.41 million, based on the following breakdown:

Total Gross Profit: $481.11 million
Total Operating Expenses: $1.00 billion

Over the last 8 years, BridgeBio Pharma's total revenue changed from $0.00 in 2017 to $502.08 million in 2025, a change of 50,207,600,000.0%.

BridgeBio Pharma's total liabilities were at $3.01 billion at the end of 2025, a 26.7% increase from 2024, and a 3,339.9% increase since 2018.

In the past 7 years, BridgeBio Pharma's cash and equivalents has ranged from $356.08 million in 2020 to $681.10 million in 2024, and is currently $570.12 million as of their latest financial filing in 2025.

Over the last 8 years, BridgeBio Pharma's book value per share changed from 0.00 in 2017 to -10.83 in 2025, a change of -1,082.8%.

Related Companies

Financial statements for NASDAQ:BBIO last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Financials

Financials Breakdown Chart

Key Financial Trends

BridgeBio Pharma Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Financials

Annual Income Statements for BridgeBio Pharma

Quarterly Income Statements for BridgeBio Pharma

Annual Cash Flow Statements for BridgeBio Pharma

Quarterly Cash Flow Statements for BridgeBio Pharma

Annual Balance Sheets for BridgeBio Pharma

Quarterly Balance Sheets for BridgeBio Pharma

Annual Metrics And Ratios for BridgeBio Pharma

Quarterly Metrics And Ratios for BridgeBio Pharma

Financials Breakdown Chart

Key Financial Trends

BridgeBio Pharma Financials - Frequently Asked Questions

When does BridgeBio Pharma's financial year end?

How has BridgeBio Pharma's net income changed over the last 8 years?

What is BridgeBio Pharma's operating income?

How has BridgeBio Pharma's revenue changed over the last 8 years?

How much debt does BridgeBio Pharma have?

How much cash does BridgeBio Pharma have?

How has BridgeBio Pharma's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools